Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease
- PMID: 23395155
- DOI: 10.1016/j.coph.2013.01.006
Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease
Abstract
Nitric oxide (NO) produced by the endothelial NO synthase (eNOS) is an antihypertensive, antithrombotic and anti-atherosclerotic molecule. Hypercholesterolemia leads to a reduction in vascular NO bioavailability. This is attributed to a dysfunction of the eNOS enzyme and a reduced eNOS activity. NADPH oxidase-mediated oxidative stress leads to oxidation of tetrahydrobiopterin (BH4), the essential cofactor of eNOS. In BH4 deficiency, oxygen reduction uncouples from NO synthesis, thereby converting eNOS to a superoxide-producing enzyme. As a consequence of eNOS uncoupling, NO production is reduced and the pre-existing oxidative stress is enhanced, which contribute significantly to atherogenesis. Therefore, pharmacological approaches that prevent eNOS uncoupling and enhance eNOS activity are of therapeutic interest. Angiotensin-converting enzyme inhibitors, AT1 receptor blockers, statins, nebivolol and resveratrol have been shown to reverse eNOS uncoupling and to stimulate eNOS activity concurrently. Molecular mechanisms of the aforementioned drugs/compounds on eNOS functionality is summarized and discussed in this review.
Copyright © 2013. Published by Elsevier Ltd.
Similar articles
-
Uncoupling of endothelial nitric oxide synthase in cerebral vasculature of Tg2576 mice.J Neurochem. 2015 Sep;134(6):1129-38. doi: 10.1111/jnc.13205. Epub 2015 Jul 15. J Neurochem. 2015. PMID: 26111938 Free PMC article.
-
Pharmacological prevention of eNOS uncoupling.Curr Pharm Des. 2014;20(22):3595-606. doi: 10.2174/13816128113196660749. Curr Pharm Des. 2014. PMID: 24180386 Review.
-
Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling.Br J Pharmacol. 2011 Sep;164(2):213-23. doi: 10.1111/j.1476-5381.2010.01196.x. Br J Pharmacol. 2011. PMID: 21198553 Free PMC article. Review.
-
Prevention of atherosclerosis by interference with the vascular nitric oxide system.Curr Pharm Des. 2009;15(27):3133-45. doi: 10.2174/138161209789058002. Curr Pharm Des. 2009. PMID: 19754387 Review.
-
Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal.Biol Chem. 2006 Dec;387(12):1521-33. doi: 10.1515/BC.2006.190. Biol Chem. 2006. PMID: 17132097 Review.
Cited by
-
Endothelial Reprogramming in Atherosclerosis.Bioengineering (Basel). 2024 Mar 27;11(4):325. doi: 10.3390/bioengineering11040325. Bioengineering (Basel). 2024. PMID: 38671747 Free PMC article. Review.
-
Resveratrol and vascular health: evidence from clinical studies and mechanisms of actions related to its metabolites produced by gut microbiota.Front Pharmacol. 2024 Mar 18;15:1368949. doi: 10.3389/fphar.2024.1368949. eCollection 2024. Front Pharmacol. 2024. PMID: 38562461 Free PMC article. Review.
-
Ginsenoside Rb1 prevents age-related endothelial senescence by modulating SIRT1/caveolin-1/enos signaling pathway.Heliyon. 2024 Jan 17;10(3):e24586. doi: 10.1016/j.heliyon.2024.e24586. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38322899 Free PMC article.
-
Resveratrol and beyond: The Effect of Natural Polyphenols on the Cardiovascular System: A Narrative Review.Biomedicines. 2023 Oct 25;11(11):2888. doi: 10.3390/biomedicines11112888. Biomedicines. 2023. PMID: 38001889 Free PMC article. Review.
-
Nitric oxide and thiols: Chemical biology, signalling paradigms and vascular therapeutic potential.Br J Pharmacol. 2023 Oct 31:10.1111/bph.16274. doi: 10.1111/bph.16274. Online ahead of print. Br J Pharmacol. 2023. PMID: 37908126 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials